PDF(Pubmed)
Abstract：
Gliomas are the most common and malignant primary tumors of the central nervous system (CNS). Glioblastomas are the most malignant and aggressive form of primary brain tumors and account for the majority of brain tumor-related deaths. The current standard treatment for gliomas is surgical resection supplemented by postoperative chemotherapy. Platinum drugs are a class of chemotherapeutic drugs that affect the cell cycle, and the main site of action is the DNA of cells, which are common chemotherapeutic drugs in clinical practice. Chemotherapy with platinum drugs such as cisplatin, carboplatin, oxaliplatin, or a combination thereof is used to treat a variety of tumors. However, the results of gliomas chemotherapy are unsatisfactory, and resistance to platinum drugs is one of the important reasons. The resistance of gliomas to platinum drugs is the result of a combination of influencing factors. Decreased intracellular drug concentration, enhanced function of cell processing active products, enhanced repair ability of cellular DNA damage, and blockage of related apoptosis pathways play an important role in it. It is known that the pathogenic properties of glioma cells and the response of glioma towards platinum-based drugs are strongly influenced by non-coding RNAs, particularly, by microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). miRNAs and lncRNAs control drug sensitivity and the development of tumor resistance towards platinum drugs. This mini-review summarizes the resistance mechanisms of gliomas to platinum drugs, as well as molecules and therapies that can improve the sensitivity of gliomas to platinum drugs.
摘要：
胶质瘤是中枢神经系统（CNS）最常见和恶性的原发性肿瘤。胶质母细胞瘤是原发性脑肿瘤的最恶性和侵袭性形式，占脑肿瘤相关死亡的大多数。目前神经胶质瘤的标准治疗方法是手术切除辅以术后化疗。铂类药物是影响细胞周期的一类化疗药物，作用的主要部位是细胞的DNA，是临床上常见的化疗药物。化疗铂类药物如顺铂，卡铂,奥沙利铂,或其组合用于治疗多种肿瘤。然而,胶质瘤化疗的结果不能令人满意，而对铂类药物耐药是其重要原因之一。胶质瘤对铂类药物的耐药是多种影响因素综合作用的结果。细胞内药物浓度降低，增强细胞处理活性产物的功能，增强细胞DNA损伤的修复能力，相关凋亡通路的阻断在其中发挥了重要作用。众所周知，神经胶质瘤细胞的致病特性和神经胶质瘤对铂类药物的反应受到非编码RNA的强烈影响，特别是,由microRNAs(miRNAs)和长链非编码RNAs(lncRNAs)组成。miRNAs和lncRNAs控制药物敏感性和肿瘤对铂类药物耐药性的发展。这篇小型综述总结了胶质瘤对铂类药物的耐药机制，以及可以提高神经胶质瘤对铂类药物敏感性的分子和疗法。
